Study design and rationale of "Synergistic Effect of Combination Therapy with Cilostazol and ProbUcol on Plaque Stabilization and Lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial

BACKGROUND: Probucol, a cholesterol-lowering agent that paradoxically also lowers high-density lipoprotein cholesterol has been shown to prevent progression of atherosclerosis. The antiplatelet agent cilostazol, which has diverse antiatherogenic properties, has also been shown to reduce restenosis i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Ko, Young-Guk, Kim, Byeong-Keuk, Lee, Byoung Kwon, Kang, Woong Chol, Choi, Seung Hyuk, Kim, Sang Wook, Lee, Jong Ho, Lee, Myoungsook, Honda, Yasuhiro, Fitzerald, Peter J, Shim, Won-Heum
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2011
Teme:
Study Protocol
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033833/
https://ncbi.nlm.nih.gov/pubmed/21226953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1745-6215-12-10
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items